Home/RyCarma Therapeutics/Dr. Andrew Marks

DA

Dr. Andrew Marks

Founder

RyCarma Therapeutics

Therapeutic Areas

Cardiovascular Musculoskeletal

RyCarma Therapeutics Pipeline

Drug	Indication	Phase
Surlorian	Heart Failure	Phase 2
Rycal Program	Ryanodine Receptor 1-Related Myopathies (RYR1-RM)	Preclinical

Leadership Team at RyCarma Therapeutics

Chief Executive Officer

Jonathan Alspaugh

President & Chief Strategy Officer

View full RyCarma Therapeutics profile